The burgeoning landscape of medication for excess body fat and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 binding site agonists, significant differences in their pharmacological profiles and clinical trial results are emerging. Retatruti

Showing promise in the field of weight management therapy, retatrutide is a different approach. Beyond many current medications, retatrutide works as a twin agonist, simultaneously engaging both GLP peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) sensors. This simultaneous engagement promotes various beneficial effects, inclu